Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Republic Healthcare's Days Sales Outstanding for the
six
months ended in Jun. 2026 was 2.17.
Republic Healthcare's Days Inventory for the
six
months ended in Jun. 2026 was 99.97.
Republic Healthcare's Days Payable for the
six
months ended in Jun. 2026 was 26.23.
Therefore, Republic Healthcare's Cash Conversion Cycle (CCC) for the
six
months ended in Jun. 2026 was 75.91.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Republic Healthcare Cash Conversion Cycle Related Terms
Republic Healthcare Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Republic Healthcare's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:08357 vs HCA, THC, DVA: Cash Conversion Cycle Comparison
For the Medical Care Facilities subindustry, Republic Healthcare's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Republic Healthcare Cash Conversion Cycle vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Republic Healthcare's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Republic Healthcare's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Republic Healthcare's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Republic Healthcare (HKSE:08357) has a Cash Conversion Cycle of 75.91 as of Jun. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Republic Healthcare and its competitors.
Is Republic Healthcare's Cash Conversion Cycle too high?
Republic Healthcare's current Cash Conversion Cycle is 75.91. The Healthcare Providers & Services industry median Cash Conversion Cycle is 17.55. Republic Healthcare's value of 75.91 is 332.7% above this industry median. Overall, Republic Healthcare has a GF Score™ of 30/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Republic Healthcare's Cash Conversion Cycle compare to HCA and THC?
Republic Healthcare's Cash Conversion Cycle of 75.91 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 17.55. Republic Healthcare's value of 75.91 is 332.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 17.55, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Republic Healthcare's current Cash Conversion Cycle of 75.91 is 332.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Republic Healthcare and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 17.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Republic Healthcare's current Cash Conversion Cycle is 75.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Republic Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Republic Healthcare (HKSE:08357) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$0.09, compared to a current price of HK$0.10 — trading 14.4% above its estimated fair value. The current Cash Conversion Cycle is 75.91 and 332.7% above the Healthcare Providers & Services industry median of 17.55. Republic Healthcare's overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Republic Healthcare (HKSE:08357), the current Cash Conversion Cycle is 75.91 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Republic Healthcare (HKSE:08357) Overvalued in 2026?
Based on GuruFocus' analysis, Republic Healthcare stock appears to be overvalued.
The current stock price of HK$0.10 is trading 14.4% above its estimated GF Value™ of HK$0.09.
GuruFocus considers Republic Healthcare to be Modestly Overvalued.
Key valuation signals for HKSE:08357:
Cash Conversion Cycle: 75.91
GF Value™: HK$0.09 vs. price of HK$0.10 (14.4% above fair value)
Industry Position: 332.7% above the Healthcare Providers & Services median
No single metric tells the full story. See the HKSE:08357 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Republic Healthcare Ltd is principally engaged in the clinic business in Singapore and the provision of management advisory services. The company provides healthcare services operating a network of general practice clinics, treatment solutions for common medical conditions with a focus on sexual health and infectious diseases, and operation of a medical aesthetics clinic that focuses on providing treatment solutions for common skin conditions and basic medical aesthetics services. The company is segments are medical services and education services. The Group is engaged in the operation of medical clinics and the provision of management advisory services, pepper trading business, and healthcare-related education business. It generates maximum revenue from Singapore.
30GF Score
Get the complete analysis for HKSE:08357
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08357 has been successfully added to your 
